Jalali Yones, Lindh Liselott
Public Dental Clinic, Malmo, Sweden.
Swed Dent J. 2010;34(2):79-86.
The aim of this prospective clinical pilot study was to evaluate the pain alleviation effectiveness of two desensitizing agents (VivaSens and Seal&Protect) on 30 patients suffering from cervical dentine sensitivity (CDS) over a six month period. Analysis of possible differences in pain alleviation effect between the agents and over time was performed. Further,the experienced pain was registered in a questionnaire regarding to what extent the treatment improved oral health/life quality among the patients. The patients (23 female, 7 male) were randomly divided into two groups. Each group was treated with one of the two desensitizing agents. Sensitivity measurements were recorded before treatment (baseline) and after treatment at time points of one week and six months. The patients were asked to rate the sensitivity experienced in the area during air stimulation by marking on a Visual Analogue Scale (VAS). At six months, 27 patients (90%) had completed the clinical trial. The results showed that a significant reduction of CDS was achieved by using VivaSens or Seal&Protect after both one week and six months. However, there were no differences found on treatment effects between the two desensitizing agents. The results from the questionnaire showed that the patients experienced improved oral health/life quality when comparing the status before and after treatment (0.000 < or = p < or = 0.0021) and there were no statistically significant difference in treatment effects between the products. In conclusion, both desensitizing agents were effective in relieving cervical dentin hypersensitivity during the time course of the study as evaluated both by air stimulation and a questionnaire related to oral health/quality of life status.
这项前瞻性临床试点研究的目的是评估两种脱敏剂（VivaSens和Seal&Protect）在六个月内对30名患有颈部牙本质敏感（CDS）患者的疼痛缓解效果。对两种脱敏剂之间以及随着时间推移疼痛缓解效果的可能差异进行了分析。此外，在一份关于治疗在多大程度上改善了患者口腔健康/生活质量的问卷中记录了所经历的疼痛。患者（23名女性，7名男性）被随机分为两组。每组用两种脱敏剂中的一种进行治疗。在治疗前（基线）以及治疗后一周和六个月的时间点记录敏感性测量结果。要求患者通过在视觉模拟量表（VAS）上标记来对空气刺激期间该区域所经历的敏感性进行评分。在六个月时，27名患者（90%）完成了临床试验。结果表明，使用VivaSens或Seal&Protect在一周和六个月后CDS均显著降低。然而，两种脱敏剂在治疗效果上未发现差异。问卷结果显示，与治疗前后的状况相比，患者的口腔健康/生活质量得到了改善（P值范围为0.000≤P≤0.0021），并且两种产品在治疗效果上无统计学显著差异。总之，在所研究的时间段内，通过空气刺激以及与口腔健康/生活质量状况相关的问卷评估，两种脱敏剂在缓解颈部牙本质过敏方面均有效。
